UNSPSC 51313429: Doxylamine chlorotheophyllinate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier POI7XGQ1HN, chemically known as 1h-purine-2,6-dione, 8-chloro-3,9-dihydro-1,3-dimethyl-, compd. with n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine (1:1), but more generally known as doxylamine chlorotheophyllinate, which bears US NIH Compound Identifier 31834.

European Medicines Agency schedules doxylamine chlorotheophyllinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. Most nations, for tariff purposes, schedule doxylamine chlorotheophyllinate under HS 29333999. SMILES: CC(C1CCCCC1)(C2CCCCN2)OCCN(C)C.CN1C2C(C(=O)N(C1=O)C)[NH]C(N2)CL.

UNSPSC 51313429 Doxylamine chlorotheophyllinate (Commodity) covers pharmaceutical products and related health-care supplies that state and local governments procure through formal competitive bidding, though recent solicitations under this code show limited direct alignment with the nominal commodity name itself. Recent opportunities tagged to this code reflect a broader pattern of state and local pharmaceutical procurement: Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems; the Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer pharmacy benefit models; and the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. The issuing bodies span county health departments, state health and human services agencies, and cooperative purchasing alliances that serve multiple state and local members, reflecting consolidation of pharmaceutical procurement through centralized or regional vehicles.

Geographic activity clusters in the South (Florida, Texas) and Upper Midwest (Minnesota, Oregon participating through MMCAP), though the cooperative purchasing structure of MMCAP extends potential reach across multiple jurisdictions. The Seminole County IFB (IFB60459723LAS) required quarterly deliveries of 1,900 naloxone units and 800 deactivation systems annually with responses due July 26, 2023, under a two-year term with one-year renewal option. The Minnesota MMCAP RFP (S1070000015802) sought manufacturers of generic pharmaceuticals and OTC products with pricing due March 26, 2026 and contract effectiveness July 1, 2026, requiring compliance with cGMP, DSCSA, and FDA standards; a 3 percent administrative fee was mandatory. The Texas RFI (HHS0017013, April 2026) functioned as preliminary market intelligence for future direct-to-manufacturer pharmacy models rather than a formal award. Vendors pursuing this code should expect compliance with federal and state pharmaceutical regulations, insurance coverage requirements ranging from $2 million to $5 million, and procurement through both traditional IFBs and cooperative purchasing agreements.